Related Experiment Video
Updated: Nov 2, 2025

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
Published on: June 12, 2021
Effectiveness of a simple medication adjustment protocol for optimizing peri-cardioversion rate control: A derivation
Nelson Lu1, Jenny MacGillivray2, Jason G Andrade3
1Department of Medicine, University of British Columbia, Vancouver, Canada.
Insights
A new protocol optimizes rate control medications before direct-current cardioversion (DCCV) for atrial fibrillation (AF). This simple adjustment strategy improves heart rate control and minimizes risks like bradycardia or pacing needs.
Area of Science:
- Cardiology
- Pharmacology
- Medical Procedures
Background:
- Persistent atrial fibrillation (AF) management relies on rate control medications.
- No established guidelines exist for adjusting these medications before direct-current cardioversion (DCCV).
Purpose of the Study:
- To develop and validate a pre-DCCV medication adjustment protocol.
- To maintain optimal rate control during DCCV.
- To minimize risks such as bradycardia, pauses, pacing, and CPR post-DCCV.
Main Methods:
- A medication adjustment protocol was derived and validated in patients undergoing elective DCCV for persistent AF.
- The protocol involved adjusting atrioventricular (AV) nodal blockers based on heart rate (HR) two days prior to DCCV.
- The protocol was tested prospectively and compared against standard care.
Main Results:
- The derived protocol involved continuing, reducing, or holding AV nodal blockers based on pre-DCCV HR.
- The protocol significantly improved peri-DCCV rate control (82% vs. 62%, P < .001) in the validation cohort.
- No instances of prolonged pauses, need for pacing, or CPR were observed post-DCCV.
Conclusions:
- A simple preprocedural medication adjustment protocol effectively optimizes peri-DCCV rate control in AF patients.
- This strategy enhances procedural safety and efficacy.
- The protocol offers a practical approach for clinicians managing AF patients undergoing DCCV.
Background:
Rate control medications are foundational in the management of persistent atrial fibrillation (AF). There are no guidelines for adjusting these medications prior to elective direct-current cardioversion (DCCV).
Objective:
To derive and validate a preprocedural medication adjustment protocol that maintains peri-DCCV rate control and minimizes risk of postconversion bradycardia, pauses, need for pacing, and cardiopulmonary resuscitation (CPR).
Methods:
Consecutive patients with persistent AF awaiting elective DCCV across 2 hospitals were screened for inclusion into derivation, validation, and control cohorts. In the derivation cohort, each patient taking an atrioventricular (AV) nodal blocker had medications adjusted based on heart rate (HR) 2 days before DCCV, and the magnitude of dose adjustment was compared with peri-DCCV HR. The adjustment protocol that achieved the highest percentage of optimal peri-DCCV rate control was tested prospectively in the validation cohort and compared to a standard-of-care control group.
Results:
The optimal protocol from the derivation cohort (n = 71), based on the 2-day pre-DCCV HR, was to (1) CONTINUE AV nodal blocker for HR ≥ 100 beats per minute (bpm), (2) reduce dose by ONE increment when 80-99 bpm, (3) reduce dose by TWO increments when 60-79 bpm, and (4) HOLD when <60 bpm. In the prospective validation cohort (n = 106), this protocol improved peri-DCCV rate control (82% vs 62%, P < .001) compared to current standard of care (n = 107). There were no conversion pauses ≥5 seconds, need for pacing, or CPR post-DCCV.
Conclusion:
This simple preprocedural medication adjustment protocol provides an effective strategy of optimizing peri-DCCV rate control in patients with AF.
Related Concept Videos
Cardiomyopathy V: Interprofessional Care
Dysrhythmias VI: Management of Dysrhythmias
Cardiopulmonary Resuscitation IV: Pharmacological Management
Cardiomyopathy II: Dilated Cardiomyopathy
Heart Failure V: Medical Management
Mitral Regurgitation III: Medical Management

